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ABSTRACT 
BACKGROUND: Recurrent antimicrobial interventions and disease-related intestinal 
dysfunction are suspected to contribute to the dysbiosis of the gastrointestinal 
microbial ecosystem in patients with cystic fibrosis (CF). The present study set out to 
detect and identify microbial discriminants in the gut microbiota composition that are 25 
associated with CF-related intestinal dysbiosis.  
METHODS: An in-depth description of CF-associated gut dysbiosis was obtained by 
screening denaturing gradient gel electrophoresis (DGGE) fingerprints for potentially 
discriminating bacterial species, and quantification by means of real-time PCR 
analyses using group-specific primers. 30 
RESULTS: A total of 8 DGGE band-classes assigned to the genus Bifidobacterium 
(n=3), and members of Clostridium clusters XIVa (n=3) and IV (n=2), were 
significantly (p<0.05) underrepresented in samples of patients with CF. Real-time 
PCR analyses confirmed a significantly lower abundance and temporal stability of 
bifidobacteria and Clostridium cluster XIVa in the faecal microbiota of patients with 35 
CF.  
CONCLUSION: This study is the first to report specific microbial determinants of 
dysbiosis in patients with CF.  
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1. INTRODUCTION 
 Chronic pulmonary infections in patients with cystic fibrosis (CF) are controlled 40 
with frequent antimicrobial administration. Although essential to restrain lung function 
decline, antimicrobial therapies disturb the balance of the gastrointestinal (GI) 
microbial ecosystem, also known as GI dysbiosis.  
 In populations without underlying chronic disease the selective pressure of 
prolonged antibiotic treatment can trigger a substantial reduction of metabolically 45 
important bacterial groups [1, 2], favour selection of antimicrobial resistant strains [3] 
and decrease colonization resistance, eliciting overgrowth by potentially pathogenic 
microorganisms [4]. Moreover, several studies have reported a long-term post-
treatment perturbation [5-8]. In young children, antibiotic-associated GI dysbiosis 
might have severe consequences for their quality of life by disturbing the maturation 50 
of the mucosa-associated lymphoid system [9-12] and inadequate immune 
development [13, 14], thus increasing the risk for acquiring infections. 
 In addition to antimicrobial interventions, dysbiosis in patients with CF could 
also result from the specific dietary regimen. Several studies have indicated that a 
positive correlation exists between alimentary habits early in life and improvement of 55 
CF lung function through stimulation of the mucosal immune defense maturation [15-
17]. Furthermore, it has been shown that GI dysbiosis can be induced by a high-fat, 
calorie-rich diet [18].  
 Using a culture dependent approach combined with molecular fingerprinting 
we previously found evidence for a compositional perturbation and substantially 60 
decreased temporal stability of the faecal microbiota in a group of patients with CF 
[19]. We now present the results of a follow-up study aiming at identifying specific 
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bacterial groups that can be considered determinants for intestinal dysbiosis in 
patients with CF.  
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2. MATERIALS AND METHODS 65 
2.1 Ethics statement. All eligible candidates for this survey and their parents 
received written information detailing the intent of the study. As the study only 
included a non-invasive sampling procedure for which the participants' willingness to 
provide the samples was mandatory, the Ethics Committee of the University of 
Leuven, Belgium, approved verbal informed consent obtained from both 70 
parents/guidance and participating children (no. ML4698). 
2.2 Participants. Faecal samples of 21 family units were analysed in this study. A 
family unit was defined as one patient with CF and one to two healthy siblings. All 
patients had a history of antibiotic treatment prior to and/or during the sampling 
period [19]. For 9 of these family units, 4 to 8 faecal samples collected between 2007 75 
and 2009 were analysed in a longitudinal study (table 1); in addition, one sample of 
each of the study participants was analysed in a cross-sectional study.  
2.3 Sample preparation. Stool samples were thawed at room temperature, and 1 g 
(wet weight) was homogenized in 9 ml Peptone Buffered Saline (PBS) (0.1 % w/v 
bacteriological peptone [catalog no. L37; Oxoid, Basingstoke, UK], 0.85 % w/v NaCl). 80 
1 ml of the resulting faecal solution was used for DNA extraction as previously 
described [20, 21].  
2.4 Denaturing Gradient Gel Electrophoresis (DGGE). Cross-sectional study 
DGGE fingerprints of 21 patients with CF and 24 healthy siblings, and longitudinal 
study DGGE fingerprints of 2 family units were available from a previous study [19]. 85 
Novel DGGE-PCR experiments were performed as previously described [19], on 
longitudinal samples from 7 additional family units using universal bacterial primers 
targeting the hyper-variable V3 region of the 16S rRNA gene. The resulting 16S 
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rRNA amplicons were separated by DGGE fingerprinting using the D-code System 
(Bio-Rad, Nazareth, Belgium) with a 35-70% linear gradient (100% denaturing 90 
polyacrylamide solution containing 7M urea (EC-605, National Diagnostics) and 40% 
formamide (F-9037, Sigma, St. Louis, USA)).  
2.5 DGGE gel band matching, extraction and sequencing. Upon normalization, all 
fingerprint profiles were subjected to band-class analysis as described by Joossens 
and coworkers [22]. Non-parametric Mann-Whitney-U tests were performed to screen 95 
for potentially discriminating band-classes in fingerprint profiles of patients with CF 
and healthy siblings. P-values of less than 0.05 were considered significant and 
multiple-testing errors were corrected by using the adapted Benjamini-Hochberg 
method [23]. Bands representing potentially discriminating band-classes were 
excised from the DGGE gel and sequenced as previously described [24]. The web-100 
based EzTaxon Server v2.1, a manually annotated and curated database of 16S 
ribosomal RNA gene sequences for bacterial type strains with validly described 
species names, was used to allocate sequenced bands to species based on 16S 
rRNA gene sequence similarities [25]. The V3-16S rRNA gene sequences determined 
in this study have been deposited in the EMBL database under accession numbers 105 
HE617671 to HE617678. 
2.6 Real-time PCR. Based on the results of DGGE band discriminant analysis, 
concentrations of faecal bifidobacteria and members of Clostridium cluster XIVa were 
determined with real-time PCR using the LightCycler system I (Roche, Mannheim, 
Germany) and the SensiMixTM Capillary Kit (QT405-05, Bioline, London, UK). 110 
Bifidobacteria were quantified using Bifidobacterium-specific primers g-Bifid-F (5' 
CTCCTGGAAACGGGTGG 3') and g-Bifid-R (5' GGTGTTCTTCCCGATATCTACA 3') 
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[26], and a calibration curve was constructed based on a serial dilution of DNA from 
Bifidobacterium breve LMG 13208T from which anaerobic plate counts were obtained 
on Modified Columbia agar [27]. For quantification of Clostridium cluster XIVa 115 
members, previously described group-specific primers g-Ccoc-F (5’ AAA TGA CGG 
TAC CTG ACT AA 3’) and g-Ccoc-R (5’ CTT TGA GTT TCA TTC TTG CGA A 3’) 
were used [28] and anaerobic enumeration of Ruminococcus torques strain L2-14 
onto medium YCFAGSC [29] was performed for construction of the calibration curve. 
The 20 µl reaction mixture contained 4 µl SensiMixTM Lite (Bioline Ltd., London, UK), 120 
0.4 µl 50*SYBR® Green I solution (Bioline Ltd.), 1.5 µl enzyme mix (Bioline Ltd.), 8.1 
µl MQ water, 5 µM of each primer (Sigma Aldrich, Bornem, Belgium) and 2 µl 
bacterial DNA. The real-time PCR program consisted of initial denaturation at 94°C 
for 5 min, followed by 40 cycles of denaturation for 20 s at 94°C, annealing at 65°C 
(genus Bifidobacterium) or 55°C ( Clostridium cluster XIVa) for 20 s and elongation at 125 
72°C for 50 s. SYBR green fluorescence was detected  at the end of each 
amplification step. Melting curve analyses were performed by slowly increasing the 
temperature from 60°C to 95°C (genus  Bifidobacterium) or 75°C to 95°C ( Clostridium 
cluster XIVa). Measurements were performed in triplicate, and were repeated when 
variation between measurements exceeded 0.5 Ct. 130 
2.8 Statistical analyses of real-time PCR data. The longitudinal datasets were 
analysed with a linear mixed model that accounts for the temporal variation between 
consecutive samples of each subject nested within a family unit. Samples of the 
cross-sectional study were compared with parametric one-tailed paired t-tests. In 
addition, the effect of several clinical parameters including forced expiratory volume 135 
in one second (FEV1), forced vital capacity (FCV), age, weight for height and gender 
was assessed. Statistical analyses were performed using SAS version 9.4 with p-
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values of less than 0.05 considered significant. Faecal concentrations were 
expressed as log10 colony forming units (CFU) per gram wet weight stool. 
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3. RESULTS 140 
3.1 DGGE fingerprint analysis of longitudinal samples. The DGGE study of nine 
family units, in which per subject 4 to 8 samples obtained over a two year period 
were included, yielded a total of 103 DGGE profiles which were investigated for the 
presence of potentially discriminating band-classes. The total number of band-
classes present in more than half of the CF samples or sibling samples, ranged from 145 
6 to 24 per family unit. Statistical analysis of these band-classes revealed significant 
differences between samples of patients with CF and healthy siblings (Mann-
Whitney-U test, p<0.05) in six family units, with each unit displaying 1 to 7 potentially 
discriminating bands. Benjamini-Hochberg correction for multiple testing reduced 
these results to five family units with the number of significant band-classes ranging 150 
from 1 to 6 per family unit (table 2). For each of these discriminating band-classes, 
bands were significantly more represented in sibling samples compared to samples 
of the corresponding patient with CF (figure 1). In total 8 different band-classes 
displayed a significant difference between samples of patients with CF and healthy 
siblings: band-class 8.90 was significantly underrepresented in faecal samples of 155 
patients in five out of the six family units, band-class 16.27 was discriminative in 
three family units, band-classes 10.22 and 14.02 were underrepresented in patient 
samples of 2 family units, and band-classes 3.79, 9.46, 11.46 and 16.05 were 
underrepresented in one family unit only.  
 Sequence analysis of DNA amplicons corresponding to band-classes 14.02, 160 
16.05 and 16.27 revealed 100% 16S rRNA gene sequence identity with 
Bifidobacterium longum, Bifidobacterium catenulatum/ Bifidobacterium 
pseudocatenulatum/ Bifidobacterium kashiwanohense (the 140-144 bp V3-16S rRNA 
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fragment does not allow differentiation of closely related bacterial species) and 
Bifidobacterium adolescentis/ Bifidobacterium ruminantium/ Bifidobacterium stercoris, 165 
respectively (table 3). Subsequent DGGE band position analysis [30] with type and 
reference strains of these Bifidobacterium species, indicated that only B. 
adolescentis co-migrated with  band-class 16.27, and that only B. catenulatum and B. 
pseudocatenulatum co-migrated with band-class 16.05 (figure S1). We therefore 
tentatively identified the bacteria represented by band-classes 14.02, 16.05 and 170 
16.27 as B. longum, B. catenulatum/ B. pseudocatenulatum and B. adolescentis, 
respectively. 
 In addition, DNA amplicons corresponding to band-classes 3.79 and 11.46 
showed the highest sequence similarity with Ruminococcus bromii (97.8%) and 
Faecalibacterium prausnitzii (98.5%), respectively (table 3). Both species are 175 
members of Clostridium cluster IV [31]. DNA amplicons corresponding to band-class 
8.90 showed 100% sequence similarity with Eubacterium contortum, Clostridium 
oroticum and Eubacterium fissicatena; DNA amplicons of band-class 9.46 showed 
100% sequence similarity to five species of the genus Blautia (table 3), and  DNA 
amplicons corresponding to band-class 10.22 showed 99.3% sequence similarity to 180 
five different species, namely Ruminococcus lactaris, Ruminococcus gauvreauii, 
Eubacterium xylanophilum, Clostridium herbivorans and Acetovibrio ethanogignens, 
of which the latter three have not been isolated from human stool before. Band-
classes 8.90, 9.46 and 10.22 each represent members of Clostridium cluster XIVa 
[31]. 185 
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3.2 DGGE fingerprint analysis of cross-sectional samples. In parallel with the 
longitudinal study, a cross-sectional dataset consisting of 42 samples from 20 
patients with CF and 22 siblings was screened for potentially discriminating band-
classes. However, none of the band-classes was found to represent a significant 190 
difference between both groups. 
3.3 Real-time PCR analyses. The 8 discriminative DGGE band-classes identified in 
this study represent three major components of the human GI microbiota, namely the 
genus Bifidobacterium and Clostridium clusters IV and XIVa [31]. Subsequent 
quantification experiments did not include Clostridium cluster IV as it was 195 
represented by two band-classes, each detected in only one family unit., whereas  
Bifidobacterium band-classes (i.e. 14.00, 16.05 and 16.27) were significantly 
underrepresented in faecal samples of patients with CF in 5 out of the 6 family units 
and Clostridium cluster XIVa band-classes (i.e. 8.90, 9.46 and 10.22) were 
significantly underrepresented in samples of patients with CF in all but one family unit.  200 
Figure 2 shows the temporal variation of bifidobacterial abundance in the five family 
units where bifidobacteria were significantly underrepresented as determined by 
band-class analysis. CF samples consistently displayed lower bifidobacterial 
concentrations (figure 2). In addition, although not statistically significant (linear 
mixed model, p=0.16) visual inspection of these data revealed a stronger temporal 205 
variation in bifidobacterial abundance in samples of patients with CF compared to 
healthy siblings throughout (figure 2). 
Furthermore, a cross-sectional analysis was conducted investigating the first 
sample of 21 family units. Although DGGE band-class analysis did not reveal any 
discriminatory potential of bifidobacteria, real-time PCR analysis revealed a 210 
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significantly higher Bifidobacterium abundance in samples from healthy siblings 
(8.71±0.13 mean log10 CFU/g stool) compared to patient samples (7.97±0.26 mean 
log10 CFU/g stool) (one-tailed paired t-test, p=0.003) (figure 3).  
Figure 4 shows the temporal variation of the Clostridium cluster XIVa abundance in 
the five family units where these bacteria were consistently underrepresented in 215 
samples of patients with CF. In addition, analysis of the temporal variation of 
Clostridium cluster XIVa abundance per family unit again revealed a higher temporal 
variation between the different sampling points of the patients with CF compared to 
their healthy siblings (figure 4), which however, was not significant between both 
groups (linear mixed model, p=0.39). 220 
Although members of Clostridium cluster XIVa were not discriminatory in the 
cross-sectional dataset using DGGE band class analysis, real-time PCR analysis 
revealed a significantly lower abundance of these bacteria in samples of patients with 
CF (6.51±0.17 mean log10 CFU/g stool) compared to samples of healthy siblings 
(7.14±0.09 mean log10 CFU/g stool) (one-tailed paired t-test, p=0.006) (figure 3). 225 
Moreover, for both groups Clostridium cluster XIVa abundance and the weight for 
height parameter were positively correlated (linear mixed model, p=0.03) (figure 5). 
This correlation, however, diminished with age (linear mixed model, p=0.041). In 
addition, patients with a low weight for height parameter revealed much lower 
abundance of Clostridium cluster XIVa compared to healthy siblings with a low 230 
weight for height parameter (figure 5).  
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DISCUSSION 
We previously reported that the predominant faecal microbiota of children with CF is 
characterized by a compositional disturbance of the total faecal microbiota and 
decreased temporal stability [19]. The present study expanded the 2-year longitudinal 235 
study from two to nine familial units in order to obtain more statistically sound results, 
identified the microbial components of the dysbiosis using band-class analysis of the 
community fingerprints, and applied real-time PCR to confirm and quantify the most 
important observations. We showed that members of the genus Bifidobacterium were 
temporary unstable and significantly underrepresented in the faecal microbiota of 240 
patients with CF in comparison to their healthy siblings. Several studies, including 
one of CF patients [32], reported a substantial decline in the number of GI 
bifidobacteria during and following antimicrobial supplementation [33-37]. The 
observed reduction of bifidobacteria could be the result of their high antimicrobial 
susceptibility and reduced adhesion capacity to inflamed mucosa [38, 39]. The 245 
results of our DGGE fingerprint analyses revealed a significant reduction of bands 
assigned to B. longum, B. catenulatum/ B. pseudocatenulatum and B. adolescentis. 
These species are considered among the most important members of the 
bifidobacterial community in the GI tract [40]. High bifidobacterial species richness 
rather than high abundance is positively correlated with the maturation of the 250 
mucosal immune system [11] but an overall reduction of the bifidobacteria in children 
with CF could influence extra-intestinal disorders such as respiratory inflammation 
and even infection. Given the health-promoting features attributed to bifidobacteria 
[38, 39], their intestinal abundance is also often used as a biomarker for a well-
balanced gut microbiota. Therefore, the significant decline observed in the present 255 
study could have severe repercussions for the host's health. 
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 We also report for the first time that bacteria of Clostridium cluster XIVa [31] 
are significantly underrepresented in the faecal microbiota of CF patients. 
Furthermore, in siblings as well as patients with CF Clostridium cluster XIVa 
abundance and weight for height were positively correlated. However, patients with 260 
poorer nutritional status revealed a much lower abundance of Clostridium cluster 
XIVa compared to healthy siblings with poorer nutritional status (figure 5). Finally, 
band-classes 3.79 and 11.46 were underrepresented in samples of patients with CF. 
These band-classes were tentatively assigned to Ruminococcus bromii and 
Faecalibacterium prausnitzii, respectively, representing Clostridium cluster IV 265 
bacteria [31]. Many Clostridium clusters IV and XIVa bacteria produce butyrate as a 
result of carbohydrate fermentation. This metabolite has various important biological 
functions such as providing energy for colonocytes, eliciting an anti-inflammatory 
response, establishment and maintenance of the GI barrier, and reduction of 
intestinal permeability, and is presumed to be involved in the prevention of colorectal 270 
cancer [41-43]. Yet, the GI microbial ecosystem has a high level of functional 
redundancy and a broad phylogenetic spectrum of bacteria is capable of synthesizing 
butyrate. It is therefore unclear to which extent a significant reduction of these 
bacterial groups may have clinical consequences.   
 Frequent use of high doses of antibiotics such as amoxicillin-clavulanate likely 275 
contributed to the reported dysbiosis. In a study by Young and Schmidt [44] a 
considerable decrease in members of the Clostridium cluster XIVa and of 
bifidobacteria was noted in the faecal microbiota of a male patient after treatment 
with amoxicillin-clavulanate. Strikingly, whereas the levels of the former were 
restored after cessation of antibiotic therapy, Bifidobacterium concentrations were not. 280 
Furthermore, decreased levels of members of Clostridium clusters IV and XIVa have 
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also been reported in patients with inflammatory bowel disease [24, 45, 46], which 
could suggest that also CF-associated GI inflammation [47-49] may be involved in 
the observed dysbiosis.  
Although intensive antimicrobial treatment courses are likely to contribute to the 285 
dysbiosis in patients with CF, highly personalized antibiotic therapies did not allow 
correlating the use of specific antimicrobial compounds with a significant reduction of 
the bacterial groups. Furthermore, no significant correlation was found between 
faecal bacteria and FEV1, FCV or gender. However, it should be noted that the 
cohorts in the present study were not age-matched, gender-matched, thus limiting 290 
our evaluations. 
To our knowledge, this is the first study that identifies specific bacterial groups as 
main determinants for a dysbiosis in patients with CF. The observed 
underrepresentation and temporal instability of members of the genus 
Bifidobacterium and Clostridium clusters IV and XIVa in patients with CF could be the 295 
result from the disease-related impairment of essential gastrointestinal functions as 
well as the detrimental effects of intensive antimicrobial treatment courses. Further 
exploration of this dysbiosis at the functional level is needed to help establishing the 
role of these bacterial groups and may lead the way to alternative nutritional 
interventions with functional foods. 300 
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Figure 1. DGGE fingerprint profiles of the longitudinal study. DGGE fingerprint 440 
profiles showing the predominant faecal microbiota of a) family unit 3; b) family unit 6; c) 
family unit 11; d) family unit 14; e) family unit 16; f) family unit 18, and discriminating 
band-classes.  
Bc: Band-class, S1 to 8: Sample 1 to 8, CF: Patient with CF; SIBLING: Healthy sibling. 
 445 
Figure 2. Temporal variation of bifidobacterial abundance. Temporal variation of the 
genus Bifidobacterium in the five family units displaying one or more potentially 
discriminating bands assigned to this group. The error bars represent standard errors. 
The asterisks indicate significant differences between patients with CF and healthy 
siblings (linear mixed model, p<0.05). The intervals between the consecutive sampling 450 
points are ±3 months.  
Figure 3. Bifidobacterial and Clostridium cluster XIVa abundance in cross-
sectional study. Graphical representation of bacterial population differences as 
boxplots. Left: Boxplot displaying Bifidobacterium abundance in faecal samples of 
patients with CF (n=21) and healthy siblings (n=22) from the cross-sectional dataset. 455 
The open circle indicates an outlier value. Right: Bloxplot displaying Clostridium cluster 
XIVa abundance in faecal samples of patients with CF (n=21) and healthy siblings (n=22) 
from the cross-sectional dataset. The p-values are based on the one-tailed paired t-test. 
 
Figure 4. Temporal variation of Clostridium cluster XIVa abundance. Temporal 460 
variation of members of Clostridium cluster XIVa in the five family units displaying one or 
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more potentially discriminating bands assigned to this group. The error bars represent 
standard errors. The asterisks indicate significant differences between patients with CF 
and healthy siblings (linear mixed model, p<0.05). The intervals between the 
consecutive sampling points are ±3 months.  465 
 
Figure 5. Clostridium cluster XIVa abundance and weight for height. Scatterplot 
displaying the correlation between Clostridium cluster XIVa abundance and weight for 
height (%) (linear mixed model, p=0.03). 
 470 
